

EMU - Cross-sectional Study on Migraine Patients in Emergency Service Departments: Diagnosis and Treatment

Head :Grun-Overdyking Aurélie, Pfizer

Last update : 01/01/2018 | Version : 1 | ID : 117

General

Identification

Detailed name Cross-sectional Study on Migraine Patients in Emergency Service Departments: Diagnosis and Treatment

Sign or acronym EMU

CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation CNIL no. 906286

General Aspects

Medical area Emergency medicine
Neurology

Keywords emergency services

Scientific investigator(s) (Contact)

Name of the director Grun-Overdyking

Surname Aurélie

Address 23-25, avenue du dr Lannelongue, 75668 Paris cedex 14

Phone +33 (0)1 58 07 33 02

Email aurelie.grun-overdyking@pfizer.com

Unit Pfizer

Collaborations

Funding

Funding status Private

Details	Pfizer
Governance of the database	
Sponsor(s) or organisation(s) responsible	Pfizer
Organisation status	Private
Additional contact	
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Not-repeated cross-sectional studies (except case control studies)
Database recruitment is carried out by an intermediary	A selection of health institutions and services
Database recruitment is carried out as part of an interventional study	No
Additional information regarding sample selection.	Recruitment by participating doctors
Database objective	
Main objective	<p>Primary:</p> <ul style="list-style-type: none"> - To estimate the frequency of patients admitted with headaches and to estimate the frequency of patients diagnosed with migraine. - To characterise patients diagnosed with migraines attending emergency services based on demographic data and migraine history (age, severity). - To describe the treatment of patients diagnosed with a migraine during emergency service consultation. <p>Secondary:</p> <ul style="list-style-type: none"> - To describe the treatment of patients diagnosed with a migraine according to the type of migraine. - To describe the frequency of patients diagnosed with a migraine and their treatment by emergency structure type. - To describe treatment follow-up.
Inclusion criteria	<ul style="list-style-type: none"> - Patients aged 18 or older. - Patients deemed capable of answering the

questions.

- Patients agreeing to participate in the survey.
- Patients admitted to emergency department

Population type

Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years) Great age (80 years and more)
-----	-----------------------------------------------------------------------------------------------------------------------------------------------------

Population covered	Sick population
--------------------	-----------------

Gender	Male Woman
--------	---------------

Geography area	National
----------------	----------

Detail of the geography area	Metropolitan France
------------------------------	---------------------

Data collection

Dates

Date of first collection (YYYY or MM/YYYY)	2006
--------------------------------------------	------

Date of last collection (YYYY or MM/YYYY)	2008
-------------------------------------------	------

Size of the database

Size of the database (number of individuals)	< 500 individuals
----------------------------------------------	-------------------

Details of the number of individuals	479
--------------------------------------	-----

Data

Database activity	Data collection completed
-------------------	---------------------------

Type of data collected	Clinical data Declarative data
------------------------	-----------------------------------

Clinical data (detail)	Direct physical measures Medical registration
------------------------	--------------------------------------------------

Declarative data (detail)	Face to face interview
---------------------------	------------------------

Presence of a biobank	No
-----------------------	----

Health parameters studied

Health event/morbidity

Procedures

Data collection method

Paper CRF

Participant monitoring

Yes

Details on monitoring of participants

6-8 weeks

Links to administrative sources

No

Promotion and access

Promotion

Access

Terms of data access (charter for data provision, format of data, availability delay)

Submission of project to the Pfizer scientific team.

Access to aggregated data

Access on specific project only

Access to individual data

Access on specific project only